Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 6:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Over Age 60 Clear all
Completed Phase 2 Interventional

Lutein for Age-Related Macular Degeneration

NCT00006202
View directory record Official record
Conditions
Macular Degeneration
Interventions
Lutein
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 3, 2026, 6:16 PM EDT
Completed Phase 3 Interventional Results available

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission

NCT00093470
View directory record Official record
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Adult Acute Myeloid Leukemia
Interventions
Clinical Observation, Tipifarnib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
339
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 228 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 3, 2026, 6:16 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age

NCT03834688
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Venetoclax, Bendamustine, Rituximab
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
60 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Urbana, Illinois • Indianapolis, Indiana • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 3, 2026, 6:16 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS

NCT00574548
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
13 valent Pneumococcal Conjugate Vaccine, 23-valent Pneumococcal Polysaccharide Vaccine
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
60 Years to 64 Years
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
6
States / cities
Chandler, Arizona • Pembroke Pines, Florida • Boise, Idaho + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2011 · Synced Sep 3, 2026, 6:16 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Companion: Sensor-based Two-way Communication for Physical Activity in Older Adults

NCT04827212
View directory record Official record
Conditions
Exercise, Physical Activity
Interventions
Companion
Behavioral
Lead sponsor
Northeastern University
Other
Eligibility
60 Years to 90 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 3, 2026, 6:16 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults

NCT00380211
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine (A/H3N2, A/H1N1, and B strains), Fluarix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
6
States / cities
Miami, Florida • Lenexa, Kansas • Binghamton, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Sep 3, 2026, 6:16 PM EDT
Terminated Phase 2 Interventional Results available

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

NCT02000596
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab plus Pertuzumab, Hormonal Therapy with Anastrozole and Fulvestrant, Chemotherapy with Eribulin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
60 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Sep 3, 2026, 6:16 PM EDT
Completed Phase 2 Interventional

Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia

NCT00089050
View directory record Official record
Conditions
Leukemia
Interventions
cyclosporine, gemtuzumab ozogamicin
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
60 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 29, 2011 · Synced Sep 3, 2026, 6:16 PM EDT
Recruiting Phase 2 Interventional

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

NCT06679829
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Siltuximab, Melphalan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 3, 2026, 6:16 PM EDT
Completed Phase 2 Interventional

Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over

NCT00170768
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Darifenacin, Oxybutynin, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
60 Years and older
Enrollment
150 participants
Timeline
2005
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2008 · Synced Sep 3, 2026, 6:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60

NCT00121589
View directory record Official record
Conditions
Macular Degeneration
Interventions
Lutein
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 3, 2026, 6:16 PM EDT
Completed No phase listed Observational

Resiliency in Older Adults Undergoing Bone Marrow Transplant

NCT04188678
View directory record Official record
Conditions
Leukemia, Lymphoma, Blood Cancer, Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Non-Hodgkins Lymphoma
Interventions
Bone Marrow Transplant (BMT)
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
60 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 3, 2026, 6:16 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma

NCT02758717
View directory record Official record
Conditions
Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage IIIA Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Nivolumab
Drug · Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
Not listed
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
9
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 3, 2026, 6:16 PM EDT
Terminated Phase 2 Interventional Results available

Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

NCT00723203
View directory record Official record
Conditions
Leukemia
Interventions
panobinostat, gene expression analysis, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Sep 3, 2026, 6:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Curcumin Supplementation for the Improvement of Diabetes-related Outcomes

NCT06984640
View directory record Official record
Conditions
Over Age 60, Prediabetes or Overweight
Interventions
Curcumin, Placebo
Dietary Supplement
Lead sponsor
Oklahoma State University
Other
Eligibility
60 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Stillwater, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 3, 2026, 6:16 PM EDT